English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Hairy cell leukemia (HCL) is a rare indolent lymphoproliferative disorder clinically characterized by pancytopenia and splenomegaly [1], with high overall survival rates after treatment with purine analogues [2-4]. We report a relatively young patient with HCL presenting with widespread osteolytic disease detected by PET who was successfully treated with cladribine and ibandronate. Osteolyses are not considered a frequent complication of HCL [5] and we are aware of only one case report describing the use of PET for diagnostic purposes in this setting [6]. Resolution of bone lesions has been described after treatment with radiotherapy or cladribine [6-9], but to our knowledge, there are no data on the use of bisphosphonates in this context.

Hairy Cell Leukemia Related Osteolyses Detected by PET Successfully Treated with Cladribine and Ibandronate